AR057227A1 - Metodo para usar antagonistas de il6 con inhibidores del proteasoma - Google Patents

Metodo para usar antagonistas de il6 con inhibidores del proteasoma

Info

Publication number
AR057227A1
AR057227A1 ARP060105416A ARP060105416A AR057227A1 AR 057227 A1 AR057227 A1 AR 057227A1 AR P060105416 A ARP060105416 A AR P060105416A AR P060105416 A ARP060105416 A AR P060105416A AR 057227 A1 AR057227 A1 AR 057227A1
Authority
AR
Argentina
Prior art keywords
proteasome inhibitor
leucyl
antagonist
treatment
condition
Prior art date
Application number
ARP060105416A
Other languages
English (en)
Spanish (es)
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of AR057227A1 publication Critical patent/AR057227A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP060105416A 2005-12-09 2006-12-07 Metodo para usar antagonistas de il6 con inhibidores del proteasoma AR057227A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
AR057227A1 true AR057227A1 (es) 2007-11-21

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105416A AR057227A1 (es) 2005-12-09 2006-12-07 Metodo para usar antagonistas de il6 con inhibidores del proteasoma

Country Status (15)

Country Link
US (1) US20090022726A1 (enExample)
EP (1) EP1954310A4 (enExample)
JP (1) JP2009518447A (enExample)
KR (1) KR20080072761A (enExample)
CN (1) CN101325969A (enExample)
AR (1) AR057227A1 (enExample)
AU (1) AU2006321610A1 (enExample)
BR (1) BRPI0619498A2 (enExample)
CA (1) CA2632732A1 (enExample)
EA (1) EA014675B1 (enExample)
IL (1) IL191694A0 (enExample)
NO (1) NO20082907L (enExample)
TW (1) TW200803895A (enExample)
WO (1) WO2007067976A2 (enExample)
ZA (1) ZA200805956B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494298T1 (de) 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
SI2030981T1 (sl) 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
WO2010039762A2 (en) * 2008-10-01 2010-04-08 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising boronic acid compounds
JP5675629B2 (ja) * 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011006273A1 (en) 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
SG178190A1 (en) * 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
WO2011060179A1 (en) * 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
AU762373B2 (en) * 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
AU2004210626A1 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of IL-6 antagonists in combination with steroids to enhance apoptosis
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos

Also Published As

Publication number Publication date
US20090022726A1 (en) 2009-01-22
WO2007067976A3 (en) 2008-02-14
AU2006321610A1 (en) 2007-06-14
WO2007067976A2 (en) 2007-06-14
EA200870029A1 (ru) 2008-10-30
NO20082907L (no) 2008-08-26
JP2009518447A (ja) 2009-05-07
EP1954310A2 (en) 2008-08-13
CA2632732A1 (en) 2007-06-14
EA014675B1 (ru) 2010-12-30
EP1954310A4 (en) 2009-04-22
BRPI0619498A2 (pt) 2011-10-04
CN101325969A (zh) 2008-12-17
TW200803895A (en) 2008-01-16
ZA200805956B (en) 2009-10-28
KR20080072761A (ko) 2008-08-06
IL191694A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
ECSP078003A (es) Inhibidores de aspartil proteasas
PE20221628A1 (es) Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
ECSP088959A (es) Inhibidores heterocíclicos de aspartil-proteasa
UA89183C2 (ru) Комбинация, которая содержит антимускариновые агенты и ингибиторы pde4
BRPI0418639B8 (pt) compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
CO6160339A2 (es) Antagonistas de ccr2 para el tratamiento de fibrosis
CL2008002159A1 (es) Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad.
PE20110067A1 (es) Derivados de piperidina como inhibidores de renina
EP2425858A3 (en) Compositions for treating pain and pruritus
BRPI0605921A2 (pt) compostos orgánicos
PE20080542A1 (es) Inhibidores del virus de la hepatitis c
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
TW200633703A (en) Salts of n-[2-({3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide
EA200800791A1 (ru) Сульфонилпирролгидрохлориды, как ингибиторы гистондезацетилазы
EA200600267A1 (ru) Антагонисты мускариновых рецепторов ацетилхолина
BR112023021146A2 (pt) Compostos cristalinos de antagonistas do receptor muscarínico de acetilcolina m1
PE20170668A1 (es) Compuesto de pirazolotiazol y medicamento que comprende el mismo
PE20070352A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
CL2010001618A1 (es) Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades.
AR076113A1 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal